| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f58e027d80c9f42687e27e11d4a8cc6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2020-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d47eddb7c2b77980817e2c772f61d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3811b4649dab525afedad9156c4eead
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ebe7ab4977a68285515c38c295c8301
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13e0c3875bb1dc8145d09c52a8e3e01 |
| publicationDate |
2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021077117-A1 |
| titleOfInvention |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| abstract |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023081901-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023081317-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023137344-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11661459-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023083003-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459372-B2 |
| priorityDate |
2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |